Stereotactic Ablative Radiotherapy for Prostate Cancer
5500/20 vs. SABR or Brachytherapy for PRimary OligoMetastatic Prostate Cancer Treatment (PROMPT)
Recruiting
N/A
Interventional Study
Oligometastatic Prostate Cancer
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Male
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 168 (estimated)
- Sponsor
- British Columbia Cancer Agency · Other
Who this trial is looking for
This trial is looking for men with a specific type of prostate cancer. Participants will receive treatments to see how well they work and how they affect quality of life.
Are You a Good Fit for This Trial?
You may be able to join if
- I have signed the consent form for the study.
- I have a prostate cancer diagnosis confirmed by a doctor.
- I have not received any treatment for prostate cancer except for hormone therapy.
- I am planning to undergo long-term hormone therapy.
- I can complete quality of life questionnaires and other assessments.
- I have a performance status of 0 to 2.
- I am suitable for brachytherapy, according to the doctor.
You may not be able to join if
- I have five or more bone or organ metastases.
- I cannot receive external beam radiotherapy due to health issues.
- I have had surgery to remove part of my prostate before.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your Eligibility
About This Trial
We will investigate whether ultrahypofractionation using stereotactic ablative radiotherapy (SABR) or brachytherapy is as well-tolerated as moderately hypofractionated external beam radiotherapy (EBRT) for treating the prostate in patients with oligometastatic prostate cancer. Secondary aims include assessment of progression-free survival (PFS) and overall survival (OS) as well as cost-effectivene…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Signed study specific informed consent
* European Cooperative Oncology Group performance status 0 to 2
* Histologically confirmed adenocarcinoma of the prostate
* Any Tumor stage, any T, any N, M1
* No prior therapy for prostate cancer apart from androgen deprivation
* Planned…
Contacts